Mode of Action of C-1027, a New Macromolecular Antitumor Antibiotic with Highly Potent Cytotoxicity, on Human Hepatoma BEL-7402 Cells

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1990 Jan 1

PMID 2173979

Citations 6

Authors

Y J Xu

D D Li

Y S Zhen

Affiliations

Soon will be listed here.

Abstract

C-1027, a new macromolecular peptide antitumor antibiotic produced by a Streptomyces strain, was extremely cytotoxic to cultured cancer cells and markedly inhibited the growth of transplantable tumors in mice. As determined by tritium-labeled precursor-incorporation assay, C-1027 strongly inhibited DNA and RNA synthesis in hepatoma BEL-7402 cells without affecting protein synthesis. After incubation with the hepatoma cells for 4 h, IC50 values for [3H]-thymidine and [3H]-uridine incorporation were 0.00012 and 0.00032 microM, respectively. After 30 min incubation, C-1027 showed much stronger inhibition of [3H]-thymidine incorporation than did Adriamycin, mitomycin C or methotrexate, even at a concentration 10,000 times lower. The effect of C-1027 on pBR322 DNA suggested that the drug could cause single- or double-strand scission of DNA. As determined by flow cytometry, C-1027 delayed the progression of hepatoma cells through the S-phase and blocked the cells at G2+M. Cytological study showed that C-1027 caused a drastic reduction of the mitotic index within 1 h and that an overshot of the mitotic index occurred at 48 h. Our results indicate that C-1027 is an interesting compound with highly potent activity on cellular DNA.

Citing Articles

DNA damage by C1027 involves hydrogen atom abstraction and addition to nucleobases.

San Pedro J, Beerman T, Greenberg M Bioorg Med Chem. 2012; 20(15):4744-50.

PMID: 22748380 PMC: 3406177. DOI: 10.1016/j.bmc.2012.06.004.

Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer.

Zhang Q, Liu X, Xu S, Li C, Zhang Y, Yang J Cancer Biother Radiopharm. 2012; 27(6):384-91.

PMID: 22651685 PMC: 3394858. DOI: 10.1089/cbr.2012.1209.

Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc.

Zhen H, He Q, Zhen Y, Wang S, Liu Y, Wu W Invest New Drugs. 2010; 29(6):1188-97.

PMID: 20596749 DOI: 10.1007/s10637-010-9463-x.

Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.

Huang Y, Shang B, Zhen Y World J Gastroenterol. 2005; 11(26):3980-4.

PMID: 15996019 PMC: 4502090. DOI: 10.3748/wjg.v11.i26.3980.

Tissue distribution and excretion of 125I-lidamycin in mice and rats.

Liu Y, Li Q, Huang Y, Liu C World J Gastroenterol. 2005; 11(21):3281-4.

PMID: 15929183 PMC: 4316064. DOI: 10.3748/wjg.v11.i21.3281.

References

Konishi M, Ohkuma H, Saitoh K, Kawaguchi H, Golik J, Dubay G . Esperamicins, a novel class of potent antitumor antibiotics. I. Physico-chemical data and partial structure. J Antibiot (Tokyo). 1985; 38(11):1605-9. DOI: 10.7164/antibiotics.38.1605. View

Jiang M, Zhen Y . [Antitumor activity of bleomycin A6 against human liver cancer in cell culture and in nude mice]. Yao Xue Xue Bao. 1987; 22(12):881-5. View

Meienhofer J, Maeda H, Glaser C, CZOMBOS J, Kuromizu K . Primary structure of neocarzinostatin, an antitumor protein. Science. 1972; 178(4063):875-6. DOI: 10.1126/science.178.4063.875. View

Tunac J, Graham B, Mamber S, Dobson W, Lenzini M . Potent antitumor antibiotic complex: PD 114,759, PD 115,028, PD 119,707, and PD 119,193. J Antibiot (Tokyo). 1985; 38(10):1337-43. DOI: 10.7164/antibiotics.38.1337. View

Kiyoto S, Nishikawa M, Terano H, Kohsaka M, Aoki H, Imanaka H . New antitumor antibiotics, FR-900405 and FR-900406. II. Production, isolation, characterization and antitumor activity. J Antibiot (Tokyo). 1985; 38(7):840-8. DOI: 10.7164/antibiotics.38.840. View

Suzuki H, Nishimura T, Muto K, Tanaka N . Mechanism of action of macromomycin: DNA strand scission, inhibition of DNA synthesis and mitosis. J Antibiot (Tokyo). 1978; 31(9):875-83. DOI: 10.7164/antibiotics.31.875. View

Sawyer T, Prestayko A, Crooke S . Purification and mechanism of action of macromomycin. Cancer Res. 1979; 39(4):1180-4. View

SAMY T, Hahm K, MODEST E, Lampman G, Keutmann H, Umezawa H . Primary structure of macromomycin, an antitumor antibiotic protein. J Biol Chem. 1983; 258(1):183-91. View

Otani T, Minami Y, Marunaka T, Zhang R, Xie M . A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties. J Antibiot (Tokyo). 1988; 41(11):1580-5. DOI: 10.7164/antibiotics.41.1580. View

10.

Painter R . Rapid test to detect agents that damage human DNA. Nature. 1977; 265(5595):650-1. DOI: 10.1038/265650a0. View

11.

Fang F, Wu G . [A simple method to determine the mode of action of drugs that inhibit DNA synthesis (author's transl)]. Yao Xue Xue Bao. 1981; 16(3):238-40. View

12.

Sawada H, Tatsumi K, Sasada M, Shirakawa S, Nakamura T . Effect of neocarzinostatin on DNA synthesis in L1210 cells. Cancer Res. 1974; 34(12):3341-6. View

13.

Hu J, Xue Y, Xie M, Zhang R, Otani T, Minami Y . A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo). 1988; 41(11):1575-9. DOI: 10.7164/antibiotics.41.1575. View

14.

Yamaizumi M, Mekada E, Uchida T, Okada Y . One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978; 15(1):245-50. DOI: 10.1016/0092-8674(78)90099-5. View

15.

Zhen Y, Reardon M, Weber G . Amphotericin B: a biological response modifier in targeting against the salvage pathways. Biochem Pharmacol. 1987; 36(21):3641-6. DOI: 10.1016/0006-2952(87)90014-1. View

16.

Ebina T, Otsuki K, Seto M, Ishida N . Specific G2 block in HeLa-S3 cells by neocarzinostatin. Eur J Cancer (1965). 1975; 11(3):155-8. DOI: 10.1016/0014-2964(75)90110-3. View

17.

Zhen Y, Ming X, Yu B, Otani T, Saito H, Yamada Y . A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo). 1989; 42(8):1294-8. DOI: 10.7164/antibiotics.42.1294. View

18.

HANKA L, Dietz A, GERPHEIDE S, Kuentzel S, Martin D . CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot (Tokyo). 1978; 31(12):1211-7. DOI: 10.7164/antibiotics.31.1211. View